Am Fam Physician. 2023;107(6):642-644
Author disclosure: No relevant financial relationships.
Clinical Question
Does screening with colonoscopy result in an increased diagnosis of colorectal cancer and a larger reduction in mortality compared with the sequential use of fecal immunochemical testing (FIT)?
Evidence-Based Answer
No trials have directly compared colonoscopy and sequential FIT. The U.S. Preventive Services Task Force (USPSTF) estimates that, over a lifetime, using colonoscopy compared with FIT may avert one additional death for every approximately 500 people screened starting at 50 years of age. (Strength of Recommendation [SOR]: C, estimate from modeling projections.) There are conflicting mortality data for colonoscopy. Several cohort studies found a 68% reduced mortality compared with no screening (SOR: B, two cohort studies with long follow-up periods.); however, a recent large European randomized controlled trial (RCT) found no colorectal cancer–specific mortality reduction from colonoscopy when using an intention-to-treat analysis. (SOR: B, single large RCT.) FIT reduced colorectal cancer– specific mortality by 16% to 62% compared with no screening. (SOR: B, older RCTs and one large cohort study.)
Evidence Summary
Subscribe
From $165- Immediate, unlimited access to all AFP content
- More than 130 CME credits/year
- AAFP app access
- Print delivery available
Issue Access
$59.95- Immediate, unlimited access to this issue's content
- CME credits
- AAFP app access
- Print delivery available